89 results
424B3
OCUP
Ocuphire Pharma Inc
16 Feb 24
Prospectus supplement
4:31pm
estimates or recommendations by securities analysts;
changes in the structure of healthcare payment systems; and
developments and market conditions
8-K
esvqst
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
8-K
EX-99.1
4vu3m5xoy6t3 m5vc7
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
EX-99.1
w9h62kf
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
424B5
mwd96481nuw psff4
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
ibwc0n39uv1v7cv4k
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
EX-99.1
iqtidkgb 7ik
6 Dec 22
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6:37am
8-K
EX-99.1
i6wjrhrra 4u35j69
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
EX-99.2
bo5l cy1i4bi52kx1i
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
EX-99.1
4394f921
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
8-K
EX-99.1
y6cri qv37h4k
8 Jun 21
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
4:32pm
424B5
l5t7ax6e203gje2xz 8i
7 Jun 21
Prospectus supplement for primary offering
4:21pm